Collagen turnover in bone diseases

Current Opinion in Clinical Nutrition and Metabolic Care

Volumn 6, Issue 1, 2003, Pages 65-71

  Robins, Simon P ^a  

^a ROWETT RESEARCH INSTITUTE   (United Kingdom)

Author keywords

Biochemical markers; Biological variability; Bone resorption and formation; Osteoporosis

Indexed keywords

AMINO TERMINAL TELOPEPTIDE; BIOCHEMICAL MARKER; CARBOXY TERMINAL TELOPEPTIDE; COLLAGEN; COLLAGEN TYPE 1; DEOXYPYRIDINOLINE; ESTROGEN; HYDROXYPROLINE; PHYTOESTROGEN; PROCOLLAGEN; PYRIDINOLINE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; BIOLOGICAL MARKER;

AGED; BONE DISEASE; BONE METABOLISM; BONE TURNOVER; CHEMICAL STRUCTURE; COLLAGEN METABOLISM; DIETARY INTAKE; ENZYME IMMUNOASSAY; FEMALE; FRACTURE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; OSSIFICATION; OSTEOLYSIS; OSTEOPOROSIS; PATIENT MONITORING; POSTMENOPAUSE OSTEOPOROSIS; RADIOIMMUNOASSAY; REVIEW; BONE; METABOLISM;

BIOLOGICAL MARKERS; BONE AND BONES; BONE DISEASES; BONE RESORPTION; COLLAGEN; HUMANS; OSTEOPOROSIS;

EID: 0142134603     PISSN: 13631950     EISSN: None     Source Type: Journal    
DOI: 10.1097/00075197-200301000-00010     Document Type: Review

References (61)

1. Al-Dehaimi AW, Blumsohn A, Eastell R. Serum galactosyl hydroxylysine as a biochemical marker of bone resorption. Clin Chem 1999; 45:676-681.
2. Gomez B, Ardakani S, Evans B, et al. Monoclonal antibody assay for free urinary pyridinium cross-links. Clin Chem 1996; 42:1168-1175.
3. Robins SP, Woitge H, Hesley R, et al. Direct, enzyme-linked immunoassay for urinary deoxypyridinoline as a specific marker for measuring bone resorption. J Bone Miner Res 1994; 9:1643-1649.
4. Risteli J, Elomaa I, Niemi S, et al. Radioimmunoassay for the pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen: a new serum marker of bone collagen degradation. Clin Chem 1993; 39:635-640.
5. Fledelius C, Kolding I, Qvist P, et al. Development of a monoclonal antibody to urinary degradation products from the C-terminal telopeptide alpha 1 chain of type I collagen. Application in an enzyme immunoassay and comparison to CrossLaps ELISA. Scand J Clin Lab Invest 1997; 57:73-83.
6. Bonde M, Qvist P, Fledelius C, et al. Applications of an enzyme immunoassay for a new marker of bone resorption (CrossLaps): follow-up on hormone replacement therapy and osteoporosis risk assessment. J Clin Endocrinol Metab 1995; 80:864-868.
7. Rosenquist C, Fledelius C, Christgau S, et al. Serum CrossLaps One Step ELISA. First application of monoclonal antibodies for measurement in serum of bone-related degradation products from C-terminal telopeptides of type I collagen. Clin Chem 1998; 44:2281-2289
8. Hanson DA, Weis MA, Bollen AM, et al. A specific immunoassay for monitoring human bone resorption: quantisation of type I collagen cross-linked N-telopeptides in urine. J Bone Miner Res 1992; 7:1251-1258.
9. Clemens JD, Herrick MV, Singer FR, Eyre DR. Evidence that serum NTx (collagen-type I N-telopeptides) can act as an immunochemical marker of bone resorption. Clin Chem 1997; 43:2058-2063.
10. Melkko J, Kauppila S, Niemi S, et al. Immunoassay for intact amino-terminal propeptide of human type I procollagen. Clin Chem 1996; 42:947-954.
11. Brandt J, Krogh TN, Jensen CH, et al. Thermal instability of the trimeric structure of the N-terminal propeptide of human procollagen type I in relation to assay technology. Clin Chem 1999; 45:47-53.
12. Melkko J, Niemi S, Risteli L, Risteli J. Radioimmunoassay of the carboxyterminal propeptide of human type I procollagen. Clin Chem 1990; 36:1328-1332.
13. Swaminathan R. Biochemical markers of bone turnover. Clin Chim Acta 2001; 313:95-105.
14. Robins SP. Biochemical markers of bone resorption. In: Trull AK, Demers LM, Holt, et al., editors. Biomarkers of disease: an evidence-based approach. Cambridge: Cambridge University Press; 2002. pp. 122-132.
15. Delmas PD. Bone marker nomenclature. Bone 2001; 28:575-576.
16. Cloos PA, Christgau S. Non-enzymatic covalent modifications of proteins: mechanisms, physiological consequences and clinical applications. Matrix Biol 2002; 21:39-52. This is an excellent review detailing the mechanisms and functional significance of a wide range of possible protein modifications and their potential for providing clinically relevant information.
17. Fledelius C, Johnsen AH, Cloos PAC, et al. Characterization of urinary degradation products derived from type I collagen. Identification of a beta-isomerized Asp-Gly sequence within the C-terminal telopeptide (α1) region. J Biol Chem 1997; 272:9755-9763.
18. Brady JD, Ju J, Robins SP. Isoaspartyl bond formation within N-terminal sequences of collagen type I: implications for their use as markers of collagen degradation. Clin Sci 1999; 96:209-215.
19. Garnero P, Cloos P, Sornay-Rendu E, et al. Type I collagen racemization and isomerization and the risk of fracture in postmenopausal women: the OFELY prospective study. J Bone Miner Res 2002; 17:826-833. This paper represents a definitive study of the potential applications of newly developed markers of bone ageing in relation to bone-fracture risk in osteoporosis.
20. Robins SP, Brady JD. Collagen cross-linking and metabolism. In: Bilezikian JP, Raisz LG, Rodan GA, editors. Principles of bone biology, 2nd edn. San Diego: Academic Press; 2002. pp. 211-223.
21. Reginster JY, Henrotin Y, Christiansen C, et al. Bone resorption in postmenopausal women with normal and low BMD assessed with biochemical markers specific for telopeptide derived degradation products of collagen type I. Calcif Tissue Int 2001; 69:130-137.
22. Vergnaud P, Lunt M, Scheidt-Nave C, et al. Is the predictive power of previous fractures for new spine and non-spine fractures associated with biochemical evidence of altered bone remodelling? The EPOS study. Clin Chim Acta 2002; 322:121-132. This is a thought-provoking study that dispels some of the current dogma concerning the application of biochemical bone markers.
23. Srivastava AK, MacFarlane G, Srivastava VP, et al. A new monoclonal antibody ELISA for detection and characterization of C-telopeptide fragments of type I collagen in urine. Calcif Tissue Int 2001; 69:327-336.
24. Garnero P, Borel O, Delmas PD. Evaluation of a fully automated serum assay for C-terminal cross-linking telopeptide of type I collagen in osteoporosis. Clin Chem 2001; 47:694-702.
25. Okabe R, Nakatsuka K, Inaba M, et al. Clinical evaluation of the Elecsys beta-CrossLaps serum assay, a new assay for degradation products of type I collagen C-telopeptides. Clin Chem 2001; 47:1410-1414.
26. Crofton PM, Evans N, Taylor MR, Holland CV. Serum CrossLaps: pediatric reference intervals from birth to 19 years of age. Clin Chem 2002; 48:671-673.
27. Seibel MJ, Lang M, Geilenkeuser WJ. Interlaboratory variation of biochemical markers of bone turnover. Clin Chem 2001; 47:1443-1450.
28. Vesper HW, Demers LM, Eastell R, et al. Assessment and recommendations on factors contributing to preanalytical variability of urinary pyrldinoline and deoxypyridinoline. Clin Chem 2002; 48:220-235. This is a thorough evaluation of variables for pyridinium cross-link measurements-perhaps a model for other markers.
29. Bjarnason NH, Henriksen EE, Alexandersen P, et al. Mechanism of circadian variation in bone resorption. Bone 2002; 30:307-313. References [29-31] represent important studies contributing to a new understanding of the biological variability of biochemical bone markers.
30. Clowes JA, Robinson RT, Heller SR, et al. Acute changes of bone turnover and PTH induced by insulin and glucose: euglycemic and hypoglycemic hyperinsulinemic clamp studies. J Clin Endocrinol Metab 2002; 87:3324-3329. References [29-31] represent important studies contributing to a new understanding of the biological variability of biochemical bone markers.
31. Clowes JA, Hannon RA, Yap TS, et al. Effect of feeding on bone turnover markers and its impact on biological variability of measurements. Bone 2002; 30:886-890. References [29-31] represent important studies contributing to a new understanding of the biological variability of biochemical bone markers.
32. Scariano JK, Garry PJ, Montoya GD, et al. Critical differences in the serial measurement of three biochemical markers of bone turnover in the sera of pre- and postmenopausal women. Clin Biochem 2001; 34:639-644.
33. Zittermann A. Seasonal variation in bone turnover: dependence on calcium nutrition [Comment]. J Bone Miner Res 2001; 16:1733; discussion, 1734.
34. Wolthers OD, Heuck C, Heickendorff L. Diurnal variations in serum and urine markers of type I and type III collagen turnover in children. Clin Chem 2001; 47:1721-1722.
35. Rauch F, Georg M, Stabrey A, et al. Collagen markers deoxypyridinoiine and hydroxylysine glycosides: pediatric reference data and use for growth prediction in growth hormone-deficient children. Clin Chem 2002; 48:315-322.
36. Branca F, Valtuena S, Golden MH, Robins S. Urinary collagen cross-links as biochemical markers of growth: an evaluation of biological variables. Ann Nutr Metab 2002; 46:80-87.
37. Ducy P, Amling M, Takeda S, et al. Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass. Cell 2000; 100:197-207.
38. Sato M, Takeda N, Sarui H, et al. Association between serum leptin concentrations and bone mineral density, and biochemical markers of bone turnover in adult men. J Clin Endocrinol Metab 2001; 86:5273-5276. This paper provides important evidence for the link between adiposity and bone metabolism.
39. Johnell O, Oden A, De Laet C, et al. Biochemical indices of bone turnover and the assessment of fracture probability. Osteoporos Int 2002; 13:523-526. This is a well-argued, critical evaluation of the current situation.
40. Chailurkit LO, Ongphiphadhanakul B, Piaseu N, et al. Biochemical markers of bone turnover and response of bone mineral density to intervention in early postmenopausal women: an experience in a clinical laboratory. Clin Chem 2001; 47:1083-1088.
41. Kim MK, Chung BC, Yu VY et al. Relationships of urinary phyto-oestrogen excretion to BMD in postmenopausal women. Clin Endocrinol (Oxf) 2002; 56:321-328.
42. Bjarnason NH, Sarkar S, Duong T, et al. Six and twelve month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years of raloxifene treatment in postmenopausal osteoporosis. Osteoporos Int 2001; 12:922-930.
43. Delmas PD, Ensrud KE, Adachi JD, et al. Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J Clin Endocrinol Metab 2002; 87:3609-3617.
44. Chapurlat RD, Blackwell T, Bauer DC, Cummings SR. Changes in biochemical markers of bone turnover in women treated with raloxifene: influence of regression to the mean. Osteoporos Int 2001; 12:1006-1014. This paper covers an important topic that may have general applicability to biochemical marker studies.
45. Szulc P, Munoz F, Claustrat B, et al. Bioavailable estradiol may be an important determinant of osteoporosis in men: the MINOS study. J Clin Endocrinol Metab 2001; 86:192-199.
46. Szulc P, Garnero P, Munoz F, et al. Cross-sectional evaluation of bone metabolism in men. J Bone Miner Res 2001; 16:1642-1650.
47. Goemaere S, Van Pottelbergh I, Zmierczak H, et al. Inverse association between bone turnover rate and bone mineral density in community-dwelling men > 70 years of age: no major role of sex steroid status. Bone 2001; 29:286-291.
48. Doran PM, Riggs BL, Atkinson EJ, Khosla S. Effects of raloxifene, a selective estrogen receptor modulator, on bone turnover markers and serum sex steroid and lipid levels in elderly men. J Bone Miner Res 2001; 16:2118-2125.
49. Bell NH, Bilezikian JP, Bone HG 3rd, et al. Alendronate increases bone mass and reduces bone markers in postmenopausal African-American women. J Clin Endocrinol Metab 2002; 87:2792-2797.
50. Berenson JR, Vescio R, Henick K, et al. A Phase I, open label, dose ranging trial of intravenous bolus zoledronic acid, a novel bisphosphonate, in cancer patients with metastatic bone disease. Cancer 2001; 91:144-154.
51. Noguchi M, Noda S. Pyridinoline cross-linked carboxyterminal telopeptide of type I collagen as a useful marker for monitoring metastatic bone activity in men with prostate cancer. J Urol 2001; 166:1106-1110.
52. Lipton A, Costa L, Ali S, Demers L. Use of markers of bone turnover for monitoring bone metastases and the response to therapy. Semin Oncol 2001; 28:54-59.
53. Fukumitsu N, Uchiyama M, Mori Y, et al. Correlation of urine type I collagen-cross-linked N telopeptide levels with bone scintigraphic results in prostate cancer patients. Metabolism 2002; 51:814-818.
54. Trovas GP, Lyritis GP, Galanos A, et al. A randomized trial of nasal spray salmon calcitonin in men with idiopathic osteoporosis: effects on bone mineral density and bone markers. J Bone Miner Res 2002; 17:521-527.
55. Buclin T, Rochat MC, Burckhardt P, et al. Bioavailability and biological efficacy of a new oral formulation of salmon calcitonin in healthy volunteers. J Bone Miner Res 2002; 17:1478-1485.
56. Lacey DL, Timms E, Tan HL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998; 93:165-176.
57. Bekker PJ, Holloway D, Nakanishi A, et al. The effect of a single dose of osteoprotegerin in postmenopausal women. J Bone Miner Res 2001; 16:348-360. This is one of the first indications of the effects on bone of a potentially important new treatment for bone loss.
58. Garnero P, Borel O, Byrjalsen I, et al. The collagenolytic activity of cathepsin K is unique among mammalian proteinases. J Biol Chem 1998; 273:32347-32352.
59. Stroup G B, Lark MW, Veber DF, et al. Potent and selective inhibition of human cathepsin K leads to inhibition of bone resorption in vivo in a nonhuman primate. J Bone Miner Res 2001; 16:1739-1746. This is an important study providing evidence for the viability of a novel therapy for inhibiting bone loss.
60. Brady JD, Robins SP. Structural characterization of pyrrolic cross-links in collagen using a biotinylated Ehrlich's reagent. J Biol Chem 2001; 276:18812-18818.
61. Kleerekoper M. Biochemical markers of bone turnover: why theory, research, and clinical practice are still in conflict. Clin Chem 2001; 47:1347-1349. This is a short, but succinct, commentary which discusses, in a constructive manner, many of the problems currently associated with the application of bone markers, and points to future goals.